Oral solids endure and evolve
There are many reasons why oral solid dosage (OSD) forms remain the most popular, including their cost effectiveness, patient-friendly nature and ability to extend product lifecycles by implementing extended, controlled and rapid release formulations.
Today, the demand is for more flexible solid manufacturing capacity.
However, as demand has shifted from a ‘blockbuster’ paradigm to more complex active pharmaceutical ingredients (APIs) and smaller batches, OSD development and manufacturing poses operational challenges for pharmaceutical firms.
Torkel Gren, senior director, science and technology officer, at Recipharm spoke to Contract Pharma about the growing interest for oral solid dose development and the global capacity to manufacture these drug forms. He also outlines the potential operational challenges that pharmaceutical firms may face.
Read the full article here: https://bit.ly/2uyMk4H